The CEO's Form 144 signals intent to sell a modest block under a pre-existing 10b5-1 plan. This is not actionable as a negative signal, the plan was adopted nine months ago and recent sells have not been accompanied by negative news. Continue to monitor for any change in the trading plan (e.g., unscheduled or accelerated sales) or unexpected insider departures, but no immediate read-through.
QURE drugs
QURE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jul 6 $41.81entry
- T+1 · 4mo ago −1.08%α −1.95% · $41.36
- T+5 · 4mo ago +6.39%α +5.46% · $44.48
- T+20 · 4mo ago +0.91%α +1.32% · $42.19
- T+60 · due 7w ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO Matthew Kapusta filed a Form 144 to sell 21,082 ordinary shares valued at ~$952K. The notice indicates the sale is part of an established 10b5-1 trading plan adopted in October 2025 and cites a stock option exercise. This is a pre-planned sale with no new discretionary insider signal, and the overall insider activity (including recent prior sells) is consistent with plan-driven liquidity.
Key Facts
- Reporting person: Matthew C. Kapusta, CEO and Managing Director of uniQure N.V.
- Proposed sale: 21,082 ordinary shares via Citigroup Global Markets
- Estimated value: ~$951,932 (approx. 0.034% of market cap at $2.8B)
- Shares to be sold after filing: 21,082, with balance held of 63,067,485
- Trading plan: 10b5-1 plan adopted October 5, 2025, sale is pre-scheduled
- Recent insider sells (4 sells totaling $2.1M in 30 days) are also plan-related, not opportunistic
Financial Impact
$951,932 proposed sale, representing approximately 0.034% of market cap, immaterial
Risk Factors
- Insider selling under a 10b5-1 plan could still precede negative catalysts if the plan was set at a high stock price level, but here the plan was adopted ~9 months ago, reducing that risk
- CEO selling at all may cause short-term retail concern despite the plan context
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001973379-26-000264 |
| Document: 0001973379-26-000264-index.html | 0001973379-26-000264 |
| Document: 0001973379-26-000264.txt | 0001973379-26-000264 |
Track record
38 reports on QURE
6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers